Work

Abstract CT064: Updated results from a first-in-human phase 1,2 study of ACE-106, a highly selective and potentially best-in-class PARP1 inhibitor in advanced solid tumors

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct064

Authors: Xingyun Cai, Jian Zhang, Yu Chen, Yanxia Shi, Wei Wang, Zhanhong Chen, Jiongjie Chen

Institutions: Fudan University Shanghai Cancer Center, Fujian Provincial Cancer Hospital, Sun Yat-sen University, Sun Yat-sen University Cancer Center, Shanxi Medical University, Second Hospital of Shanxi Medical University, Zhejiang Cancer Hospital

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154682130

Cites:

Cited by: 1

Related to: